Eli Lilly and Boehringer Ingelheim Report the P-III (EMPACT-MI) Study Data of Jardiance on Risk of Heart Failure and Death Following a Heart Attack
Shots:
- The P-III (EMPACT-MI) study (part of the EMPOWER program) assesses the effect of Jardiance (10mg, QD) vs PBO alongside SoC administered within 14 days of hospitalization to prevent the risk of heart failure & mortality in adults (n=6,500) post heart attack
- The study demonstrated a risk reduction of 10% in the time to first hospitalization due to heart failure or all-cause mortality with Jardiance that was not significant
- The pre-specified exploratory analysis depicted a 23% of relative risk reduction in the time to first hospitalization & 33% for total hospitalizations due to heart failure. The results were highlighted at American College of Cardiology 2024 & published in the NEJM
Ref: Eli Lilly | Image: Eli Lilly
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
